Resapp Health Azione

Resapp Health PEG

PEG Ratio (Rapporto prezzo-utile-crescita) di Resapp Health (RAP.AX) al 12 ago 2026.

PEG

0,00

Ultimo aggiornamento:

PEG Ratio (Rapporto prezzo-utile-crescita) di Resapp Health ammonta a 2026 0,00 . PEG Ratio (Rapporto prezzo-utile-crescita) di Resapp Health ammontava a 2025 -0,11 . Diminuisce del % superiore rispetto all'anno precedente.
Access this data via the Eulerpool API

Resapp Health Analisi delle Azioni

Cosa fa Resapp Health? ResApp Health Ltd is an Australian company that focuses on the development of digital diagnostic and treatment solutions in the field of respiratory diseases. The company was founded in 2014 by Tony Keating and Philippa Lewis, both of whom have significant experience in the medical technology industry. The company aims to improve and simplify the diagnosis of respiratory diseases by developing a diagnosis based on cough and breath sounds. To achieve this, the company has developed an intelligent system based on machine learning and artificial intelligence that analyzes individual sound waves and provides an accurate diagnostic capability. ResApp Health's business model is based on the development of digital diagnostic and treatment solutions in the field of respiratory diseases, which are offered through various distribution channels. The company offers both mobile apps and clinical diagnostic systems. ResApp Health operates in various divisions at different levels. On the one hand, the company conducts research and development to continuously improve its products. On the other hand, it works closely with clinicians, scientists, and other industry experts to enable the best possible patient treatment. Products offered by ResApp Health include digital diagnostic systems in the field of respiratory diseases that function based on cough and breath sounds. The products are offered for use in both clinical practice and at home to enable fast and accurate diagnosis. Another important area in which ResApp Health operates is the treatment of respiratory diseases. The company offers digital therapy platforms tailored to the individual needs of patients, enabling improved therapy. ResApp Health has already achieved a number of important milestones. For example, in 2016, the company received CE marking for its digital diagnostic system, and in 2017, it completed a clinical study that demonstrated the system's high accuracy in diagnosing respiratory diseases. Overall, ResApp Health has great potential to play an important role in the field of diagnosis and treatment of respiratory diseases in the future. With a strong focus on research and development and close collaboration with industry experts, the company will continue to offer innovative solutions to improve patient health. Resapp Health è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su Resapp Health azioni

Su Eulerpool è possibile consultare lo sviluppo storico completo del Resapp Health di PEG Ratio (Rapporto prezzo-utile-crescita) dal 2006, con valori annuali, grafici e analisi dettagliate.

Il rapporto PEG rettifica il P/E in base al tasso di crescita atteso dei guadagni. Un PEG inferiore a 1 può indicare un'azione sottovalutata rispetto al suo potenziale di crescita.

PEG = Rapporto P/E / Tasso di crescita annuale atteso dell'EPS

Per valutare di PEG Ratio (Rapporto prezzo-utile-crescita), è essenziale confrontarlo con i competitor nello stesso settore e industria. Su Eulerpool puoi trovare confronti diretti con l'industria per PEG Ratio (Rapporto prezzo-utile-crescita).

Un 'buono' varia a seconda del settore e della fase di sviluppo dell'azienda. Su Eulerpool puoi confrontare Resapp Health di PEG Ratio (Rapporto prezzo-utile-crescita) con i competitor del settore e la media industriale per valutare se è attraente.

Access this data via the Eulerpool API

Valutazione — Resapp Health

Tutte le Metriche Finanziarie — Resapp Health